Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 182-194

  Chen, Yang ^a   Liu, Guanghua ^a   Guo, Lifang ^a   Wang, Hui ^a   Fu, Yan ^a   Luo, Yongzhang ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

EGFR; internalization; lipid rafts; nystatin; therapeutic antibody

Indexed keywords

ANTINEOPLASTIC AGENT; BIOTIN; CETUXIMAB; CETUXIMAB DOXORUBICIN CONJUGATE; CETUXIMAB METHOTREXATE CONJUGATE; CLATHRIN; NYSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN; CHOLESTEROL; DOXORUBICIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CHOLESTEROL METABOLISM; CHOLESTEROL SEQUESTRATION; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TRANSPORT; DRUG TUMOR LEVEL; ENDOCYTOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL MEMBRANE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; NUDE MOUSE; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHOLESTEROL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENDOCYTOSIS; HUMANS; MEMBRANE MICRODOMAINS; MICE, INBRED BALB C; MICE, NUDE; NYSTATIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925285534     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28950     Document Type: Article

References (49)

1. Baselga J,. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 2001; 37 Suppl 4: S16-22.
2. Ciardiello F, Tortora G,. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
3. Teicher BA,. Antibody-drug conjugate targets. Current cancer drug targets 2009; 9: 982-1004.
4. Kawaguchi Y, Kono K, Mimura K, et al., Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120: 781-7.
5. Correale P, Botta C, Cusi MG, et al., Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer 2012; 130: 1577-89.
6. Sunada H, Magun BE, Mendelsohn J, et al., Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 1986; 83: 3825-9.
7. Jaramillo ML, Leon Z, Grothe S, et al., Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 2006; 312: 2778-90.
8. Sunada H, Yu P, Peacock JS, et al., Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody. J Cell Physiol 1990; 142: 284-92.
9. Mamot C, Drummond DC, Greiser U, et al., Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 2003; 63: 3154-61.
10. Yip WL, Weyergang A, Berg K, et al., Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol Pharm 2007; 4: 241-51.
11. Schrama D, Reisfeld RA, Becker JC,. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5: 147-59.
12. Le Roy C, Wrana JL,. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 2005; 6: 112-26.
13. Parton RG, Simons K,. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8: 185-94.
14. Rejman J, Bragonzi A, Conese M,. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 2005; 12: 468-74.
15. Sigismund S, Woelk T, Puri C, et al., Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA 2005; 102: 2760-5.
16. Puri C, Tosoni D, Comai R, et al., Relationships between EGFR Signaling-competent and endocytosis-competent membrane microdomains. Mol Biol Cell 2005; 16: 2704-18.
17. Pike LJ,. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta 2005; 1746: 260-73.
18. Guglielmo GM,. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover (vol 5, pg 410, 2003). Nat Cell Biol 2003; 5: 680.
19. Caswell PT, Vadrevu S, Norman JC,. Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol 2009; 10: 843-53.
20. Lee J, Lee I, Han B, et al., Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 2011; 103: 674-88.
21. Irwin ME, Mueller KL, Bohin N, et al., Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2011; 226: 2316-28.
22. Rothberg KG, Heuser JE, Donzell WC, et al., Caveolin, a protein component of caveolae membrane coats. Cell 1992; 68: 673-82.
23. Shi HB, Huang YJ, Zhou H, et al., Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007; 110: 2899-906.
24. Chen Y, Wang S, Lu X, et al., Cholesterol sequestration by nystatin enhances the uptake and activity of endostatin in endothelium via regulating distinct endocytic pathways. Blood 2011; 117: 6392-403.
25. Taylor DR, Watt NT, Perera WS, et al., Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J Cell Sci 2005; 118: 5141-53.
26. Migalovich HS, Kalchenko V, Nevo N, et al., Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: magnetic resonance imaging and near-infrared imaging of bifunctional contrast media. Cancer Res 2009; 69: 5610-7.
27. Tedja R, Lim M, Amal R, et al., Effects of serum adsorption on cellular uptake profile and consequent impact of titanium dioxide nanoparticles on human lung cell lines. ACS Nano 2012; 6: 4083-93.
28. Rehman ZU, Zuhorn IS, Hoekstra D,. How cationic lipids transfer nucleic acids into cells and across cellular membranes: recent advances. J Controlled Release 2013; 166: 46-56.
29. Bhattacharyya S, Bhattacharya R, Curley S, et al., Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci USA 2010; 107: 14541-6.
30. Wang F, Dufner-Beattie J, Kim BE, et al., Zinc-stimulated endocytosis controls activity of the mouse ZIP1 and ZIP3 zinc uptake transporters. J Biol Chem 2004; 279: 24631-9.
31. Griffiths GL, Mattes MJ, Stein R, et al., Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003; 9: 6567-71.
32. Sapra P, Stein R, Pickett J, et al., Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005; 11: 5257-64.
33. Deguchi T, Chu TM, Leong SS, et al., Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor. Cancer Res 1986; 46: 3751-5.
34. van de Graaf SF, Rescher U, Hoenderop JG, et al., TRPV5 is internalized via clathrin-dependent endocytosis to enter a Ca2+-controlled recycling pathway. J Biol Chem 2008; 283: 4077-86.
35. Boisvert H, Duncan MJ,. Clathrin-dependent entry of a gingipain adhesin peptide and Porphyromonas gingivalis into host cells. Cell Microbiol 2008; 10: 2538-52.
36. Arwert E, Hingtgen S, Figueiredo JL, et al., Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. Cancer Res 2007; 67: 7335-42.
37. Liu F, Liu X, Wang D, et al., A parallel excitation based fluorescence molecular tomography system for whole-body simultaneous imaging of small animals. Ann Biomed Eng 2010; 38: 3440-8.
38. Masui H, Kawamoto T, Sato JD, et al., Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44: 1002-7.
39. Raben D, Helfrich B, Chan DC, et al., The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005; 11: 795-805.
40. Jhawer M, Goel S, Wilson AJ, et al., PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953-61.
41. Wild R, Fager K, Flefleh C, et al., Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther 2006; 5: 104-13.
42. Bier H, Hoffmann T, Haas I, et al., Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998; 46: 167-73.
43. Russell KS, Stern DF, Polverini PJ, et al., Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol 1999; 277: H2205-11.
44. Baselga J, Norton L, Masui H, et al., Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327-33.
45. Subtil A, Gaidarov I, Kobylarz K, et al., Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci USA 1999; 96: 6775-80.
46. Rodal SK, Skretting G, Garred O, et al., Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol Biol Cell 1999; 10: 961-74.
47. Liu YT, Song L, Templeton DM,. Heparin suppresses lipid raft-mediated signaling and ligand-independent EGF receptor activation. J Cell Physiol 2007; 211: 205-12.
48. Bolard J,. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta 1986; 864: 257-304.
49. Ng AW, Wasan KM, Lopez-Berestein G,. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 2003; 6: 67-83.